Cargando…

The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study

Detalles Bibliográficos
Autores principales:	Trachana, M, Pratsidou-Gertsi, P, Kanakoudi-Tsakalidou, F, Diafa, C, Pardalos, G, Badouraki, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334158/ http://dx.doi.org/10.1186/1546-0096-6-S1-P93

Ejemplares similares

Impact of a 2-yr anti-TNF treatment on the quality of life in JIA patients: a parent's/patient’s view
por: Diafa, K, et al.
Publicado: (2011)

The role of synovial fluid cytokines IL-6, IL-23 and IL-17 in the pathogenesis and persistence of synovial inflammation in JIA patients
por: Tzimouli, V, et al.
Publicado: (2008)

PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
por: Pratsidou-Gertsi, P, et al.
Publicado: (2013)

The portrait of Familial Mediterranean Fever in N. Greek pediatric patients: a 30-year experience
por: Pratsidou-Gertsi, P, et al.
Publicado: (2015)

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
por: Trachana, M, et al.
Publicado: (2011)

B lymphocyte stimulator, interferon-α and HMGB 1 interrelation in childhood onset systemic lupus erythematosus: associations with disease activity and severity
por: Kanakoudi-Tsakalidou, Florence, et al.
Publicado: (2014)

PReS-FINAL-2299: Novel biomarkers for the assessment of pediatric systemic lupus erythematosus nephritis (preliminary report)
por: Koutsonikoli, A, et al.
Publicado: (2013)

A biopsychosocial approach to parents of children with juvenile idiopathic arthritis
por: Georgiadou, Z, et al.
Publicado: (2011)

Clinical remission off medication in greek adults with juvenile idiopathic arthritis during a 17 year follow-up period
por: Dimopoulou, Despoina, et al.
Publicado: (2014)

Chronic recurrent multifocal osteomyelitis in N. Greece: disease burden in pediatric patients
por: Trachana, M, et al.
Publicado: (2015)

A Greek multicenter study comparing the clinical and immunologic phenotypes between adult and juvenile- onset lupus
por: Nalbanti, P, et al.
Publicado: (2011)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Long-term impact of juvenile idiopathic arthritis in the Greek adults' psychosocial life
por: Dimopoulou, Despoina, et al.
Publicado: (2014)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani, MG, et al.
Publicado: (2008)

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Etanercept therapy in JIA: impact on the need for intra-articular steroid injections
por: Pain, CE, et al.
Publicado: (2008)

DNase I levels and disease outcome in JIA patients treated with etanercept
por: Lazarević, D, et al.
Publicado: (2011)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
por: Perfetti, F, et al.
Publicado: (2013)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Inflence of clinical and genetic characteristics on ability to achive and maintain remission in JIA patients on etanercept treatment
por: Lazarevic, Dragana S, et al.
Publicado: (2014)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Pratsidou-Gertsi, Polyxeni, et al.
Publicado: (2018)

Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2012)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
por: Rossi, L, et al.
Publicado: (2008)

Abatacept for severe anti-TNF-alfa refractory JIA-associated uveitis: one year follow-up
por: Alpigiani, MG, et al.
Publicado: (2011)

Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis
por: Baraliakos, X, et al.
Publicado: (2005)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

Ultrasonography (US) in juvenile idiopathic arthritis (JIA): diagnosis, treatment and follow-up of ankle involvement
por: Laurell, L, et al.
Publicado: (2008)

P66 Adalimumab originator versus biosimilar in children and young people with JIA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2022)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

Pain and impact of pain on function in JIA-patients aged 10-19 years
por: Lanzinger, M
Publicado: (2011)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

Determing an “autoimmune” phenotype in systemic JIA
por: Fischer, N, et al.
Publicado: (2011)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ka2idmd9sv3799rom6l8u1139s